nach oben

07.03.2024 | Review

The Role of Genetics in Advancing Cardiometabolic Drug Development

verfasst von: Roukoz Abou-Karam, Fangzhou Cheng, Shoshana Gady, Akl C. Fahed

Erschienen in: Current Atherosclerosis Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The objective of this review is to explore the role of genetics in cardiometabolic drug development. The declining costs of sequencing and the availability of large-scale genomic data have deepened our understanding of cardiometabolic diseases, revolutionizing drug discovery and development methodologies. We highlight four key areas in which genetics is empowering drug development for cardiometabolic disease: (1) identifying drug candidates, (2) anticipating drug target failures, (3) silencing and editing genes, and (4) enriching clinical trials.

Recent Findings

Identifying novel drug targets through genetic discovery studies and the use of genetic variants as indicators of potential drug efficacy and safety have become critical components of cardiometabolic drug discovery. We highlight the successes of genetically-informed therapeutic strategies, such as PCSK9 and ANGPTL3 inhibitors in lipid lowering and the emerging role of polygenic risk scores in improving the efficiency of clinical trials. Additionally, we explore the potential of gene silencing and editing technologies, such as antisense oligonucleotides and small interfering RNA, showcasing their promise in addressing diseases refractory to conventional treatments.

Summary

In this review, we highlight four use cases that demonstrate the vital role of genetics in cardiometabolic drug development: (1) identifying drug candidates, (2) anticipating drug target failures, (3) silencing and editing genes, and (4) enriching clinical trials. Through these advances, genetics has paved the way to increased efficiency of drug development as well as the discovery of more personalized and effective treatments for cardiometabolic disease.

Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147:e93-621.PubMedCrossRef

Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors. J Am Coll Cardiol. 2019;74:2529–32.PubMedCrossRef

Zhou W, Kanai M, Wu K-HH, Rasheed H, Tsuo K, Hirbo JB, et al. Global Biobank Meta-analysis Initiative: powering genetic discovery across human disease. Cell Genomics. 2022;2:100192.PubMedPubMedCentralCrossRef

The “All of Us” research program. N Engl J Med. 2019;381:668–76.

Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–9.ADSPubMedPubMedCentralCrossRef

Wouters OJ, McKee M, Luyten J. Estimated research and development investment Needed to Bring a New Medicine to Market, 2009–2018. JAMA. 2020;323:844–53.PubMedPubMedCentralCrossRef

Schuhmacher A, Hinder M, Von Stegmann Und Stein A, Hartl D, Gassmann O. Analysis of pharma R&D productivity – a new perspective needed. Drug Discov Today. 2023;28:103726.PubMedCrossRef

Moore TJ, Zhang H, Anderson G, Alexander GC. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015–2016. JAMA Intern Med. 2018;178:1451–7.PubMedPubMedCentralCrossRef

Harrison RK. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov. 2016;15:817–8.PubMedCrossRef

10.

Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011–2012. Nat Rev Drug Discov. 2013;12:569.PubMedCrossRef

11.

El Khoury P, Elbitar S, Ghaleb Y, Khalil YA, Varret M, Boileau C, et al. PCSK9 mutations in familial hypercholesterolemia: from a groundbreaking discovery to anti-PCSK9 therapies. Curr Atheroscler Rep. 2017;19:49.PubMedCrossRef

12.

• Trajanoska K, Bhérer C, Taliun D, Zhou S, Richards JB, Mooser V. From target discovery to clinical drug development with human genetics. Nature. 2023;620:737–45. This review paper details the process of translating genetic discoveries into clinical drug development.ADSPubMedCrossRef

13.

Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–60.PubMedCrossRef

14.

King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLOS Genet. 2019;15:e1008489.PubMedPubMedCentralCrossRef

15.

Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154–6.PubMedCrossRef

16.

Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220–7.PubMedPubMedCentralCrossRef

17.

Schmidt AF, Hingorani AD, Finan C. Human genomics and drug development. Cold Spring Harb Perspect Med [Internet]. 2022 [cited 2023 Dec 12];12. Available from: https://doi.org/10.1101/cshperspect.a039230

18.

•• Carss KJ, Deaton AM, Del Rio-Espinola A, Diogo D, Fielden M, Kulkarni DA, et al. Using human genetics to improve safety assessment of therapeutics. Nat Rev Drug Discov. 2023;22:145–62. This review paper highlights the role of human genetics in enhancing the safety assessment of therapeutics, which is pivotal in advancing the development of drugs that are both effective and safe.PubMedCrossRef

19.

Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017;318:1925–6.PubMedCrossRef

20.

• Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA [Internet]. 2023 [cited 2023 Nov 26]; Available from: https://doi.org/10.1001/jama.2023.21835. Findings from this study offer critical insights into the efficacy of extended-duration RNA interference therapies in targeting lipoprotein(a) paving the way for novel therapeutic approaches in the cardiometabolic field.

21.

A single infusion of a gene-editing medicine may control inherited high LDL cholesterol. Am Heart Assoc [Internet]. 2023 [cited 2023 Nov 26]; Available from: https://newsroom.heart.org/news/a-single-infusion-of-a-gene-editing-medicine-may-control-inherited-high-ldl-cholesterol

22.

•• Fahed AC, Philippakis AA, Khera AV. The potential of polygenic scores to improve cost and efficiency of clinical trials. Nat Commun. 2022;13:1–4. This article demonstrates the potential of polygenic scores in enhancing the cost-efficiency and effectiveness of clinical trials.CrossRef

23.

Precision Cardiology Laboratory [Internet]. Broad Inst. 2018 [cited 2023 Dec 12]. Available from: https://www.broadinstitute.org/precision-cardiology-laboratory

24.

Regeneron Genetics Center (RGC): genetics to therapeutics [Internet]. 2023 [cited 2023 Dec 12]. Available from: https://www.regeneron.com/science/genetics-center

25.

Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19:104–10.PubMedCrossRef

26.

Lu W, Gauthier LD, Poterba T, Giacopuzzi E, Goodrich JK, Stevens CR, et al. CHARR efficiently estimates contamination from DNA sequencing data [Internet]. bioRxiv; 2023 [cited 2023 Dec 12]. p. 2023.06.28.545801. Available from: https://www.biorxiv.org/content/10.1101/2023.06.28.545801v1

27.

Koenig Z, Yohannes MT, Nkambule LL, Goodrich JK, Kim HA, Zhao X, et al. A harmonized public resource of deeply sequenced diverse human genomes [Internet]. bioRxiv; 2023 [cited 2023 Dec 12]. p. 2023.01.23.525248. Available from: https://www.biorxiv.org/content/10.1101/2023.01.23.525248v3

28.

Bergström A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, et al. Insights into human genetic variation and population history from 929 diverse genomes. Science. 2020;367:eaay5012.PubMedPubMedCentralCrossRef

29.

Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383:711–20.PubMedCrossRef

30.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.PubMedCrossRef

31.

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.PubMedCrossRef

32.

Geisterfer-Lowrance AA, Kass S, Tanigawa G, Vosberg HP, McKenna W, Seidman CE, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999–1006.PubMedCrossRef

33.

Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res. 2021;128:1533–53.ADSPubMedPubMedCentralCrossRef

34.

Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759–69.PubMedCrossRef

35.

Baxter SM, Posey JE, Lake NJ, Sobreira N, Chong JX, Buyske S, et al. Centers for Mendelian Genomics: a decade of facilitating gene discovery. Genet Med. 2022;24:784–97.PubMedPubMedCentralCrossRef

36.

Posey JE, O’Donnell-Luria AH, Chong JX, Harel T, Jhangiani SN, Coban Akdemir ZH, et al. Insights into genetics, human biology and disease gleaned from family based genomic studies. Genet Med. 2019;21:798–812.PubMedPubMedCentralCrossRef

37.

Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54:1803–15.PubMedPubMedCentralCrossRef

38.

Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021;600:675–9.ADSPubMedPubMedCentralCrossRef

39.

Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412–25.PubMedPubMedCentralCrossRef

40.

Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54:560–72.PubMedPubMedCentralCrossRef

41.

Mizoguchi T, MacDonald BT, Bhandary B, Popp NR, Laprise D, Arduini A, et al. Coronary disease association with ADAMTS7 is due to protease activity. Circ Res. 2021;129:458–70.PubMedPubMedCentralCrossRef

42.

Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, et al. Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021;593:238–43.ADSPubMedPubMedCentralCrossRef

43.

Weeks EM, Ulirsch JC, Cheng NY, Trippe BL, Fine RS, Miao J, et al. Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases. Nat Genet. 2023;55:1267–76.PubMedPubMedCentralCrossRef

44.

Yu F, Cato LD, Weng C, Liggett LA, Jeon S, Xu K, et al. Variant to function mapping at single-cell resolution through network propagation. Nat Biotechnol. 2022;40:1644–53.PubMedPubMedCentralCrossRef

45.

Minikel EV, Karczewski KJ, Martin HC, Cummings BB, Whiffin N, Rhodes D, et al. Evaluating drug targets through human loss-of-function genetic variation. Nature. 2020;581:459–64.ADSPubMedPubMedCentralCrossRef

46.

Saleheen D, Natarajan P, Armean IM, Zhao W, Rasheed A, Khetarpal SA, et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature. 2017;544:235–9.ADSPubMedPubMedCentralCrossRef

47.

Ginsberg HN, Goldberg IJ. Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arterioscler Thromb Vasc Biol [Internet]. 2023 [cited 2023 Oct 9]; Available from: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.122.317966

48.

Emdin CA, Khera AV, Chaffin M, Klarin D, Natarajan P, Aragam K, et al. Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nat Commun. 2018;9:1613.ADSPubMedPubMedCentralCrossRef

49.

Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.PubMedCrossRef

50.

Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:428–38.PubMedCrossRef

51.

Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012;11:191–200.PubMedCrossRef

52.

Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581–94.PubMedCrossRef

53.

Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14:577–90.PubMedPubMedCentralCrossRef

54.

Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345–52.PubMedPubMedCentralCrossRef

55.

Frikke-Schmidt R, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA. 2008;299:2524–32.PubMedCrossRef

56.

Armitage J, Holmes MV, Preiss D. Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events. J Am Coll Cardiol. 2019;73:477–87.PubMedPubMedCentralCrossRef

57.

AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRef

58.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.PubMedCrossRef

59.

Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380:1033–42.PubMedPubMedCentralCrossRef

60.

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–32.PubMedCrossRef

61.

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353–64.PubMedCrossRef

62.

Diogo D, Tian C, Franklin CS, Alanne-Kinnunen M, March M, Spencer CCA, et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun. 2018;9:4285.ADSPubMedPubMedCentralCrossRef

63.

Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE. 2015;10:e0122271.PubMedPubMedCentralCrossRef

64.

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–24.

65.

Research C for BE and. Approved cellular and gene therapy products. FDA [Internet]. 2023 [cited 2023 Nov 26]; Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

66.

Musunuru K. Moving toward genome-editing therapies for cardiovascular diseases. J Clin Invest. 2022;132:e148555.PubMedPubMedCentralCrossRef

67.

Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–19.PubMedCrossRef

68.

O’Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855–64.PubMedCrossRef

69.

Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79:1035–46.PubMedCrossRef

70.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.PubMedCrossRef

71.

Joubran E, Nguyen H. Inotersen. StatPearls Internet [Internet]. StatPearls Publishing; 2023 [cited 2023 Nov 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK578206/

72.

Genome Editing [Internet]. Nature. 2022 [cited 2023 Nov 27]. Available from: https://www.nature.com/collections/rpdbdzpccx

73.

MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia [Internet]. Available from: https://www.gov.uk/government/news/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia

74.

Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci. 2008;105:1620–5.ADSPubMedPubMedCentralCrossRef

75.

Menzel S, Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39:1197–9.PubMedCrossRef

76.

Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322:1839–42.ADSPubMedCrossRef

77.

Lettre G, Sankaran VG, Bezerra MAC, Araújo AS, Uda M, Sanna S, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci. 2008;105:11869–74.ADSPubMedPubMedCentralCrossRef

78.

Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384:252–60.PubMedCrossRef

79.

Marston NA, Kamanu FK, Nordio F, Gurmu Y, Roselli C, Sever PS, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER Trial. Circulation. 2020;141:616–23.PubMedCrossRef

80.

Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES trial. Circulation. 2020;141:624–36.PubMedCrossRef

81.

Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef

82.

Research C for DE and. Enrichment strategies for clinical trials to support approval of human drugs and biological products [Internet]. FDA; 2019 Apr. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products

83.

Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. Nat Rev Cardiol. 2022;19:291–301.PubMedCrossRef

84.

Fahed AC. Polygenic risk-based detection of subclinical coronary atherosclerosis and intervention with statin and colchicine [Internet]. clinicaltrials.gov; 2023 Apr. Report No.: NCT05850091. Available from: https://clinicaltrials.gov/study/NCT05850091

85.

Fahed AC. Polygenic risk-based detection of subclinical coronary atherosclerosis and change in cardiovascular health [Internet]. clinicaltrials.gov; 2023 Apr. Report No.: NCT05819814. Available from: https://clinicaltrials.gov/study/NCT05819814

86.

Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29.PubMedPubMedCentralCrossRef

Titel: The Role of Genetics in Advancing Cardiometabolic Drug Development
verfasst von: Roukoz Abou-Karam
Fangzhou Cheng
Shoshana Gady
Akl C. Fahed
Publikationsdatum: 07.03.2024
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-024-01195-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen